Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma.
Sarkozy C, Callanan M, Thieblemont C, Obéric L, Burroni B, Bouabdallah K, Damaj G, Tessoulin B, Ribrag V, Houot R, Morschhauser F, Griolet S, Joubert C, Cacheux V, Delwail V, Safar V, Gressin R, Cheminant M, Delfau-Larue MH, Hermine O, Macintyre E, Le Gouill S. Sarkozy C, et al. Among authors: safar v. Blood. 2024 Jul 18;144(3):262-271. doi: 10.1182/blood.2024023944. Blood. 2024. PMID: 38669626 Free article. Clinical Trial.
SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma.
Fargier E, Ranchon F, Huot L, Guerre P, Safar V, Dony A, Hequet N, Bachy E, Savouroux S, Fronteau C, Tomaré P, Tournamille JF, Schwiertz V, Vantard N, Le Gouill S, Gyan E, Salles G, Rioufol C. Fargier E, et al. Among authors: safar v. Ann Hematol. 2018 Jan;97(1):123-131. doi: 10.1007/s00277-017-3147-y. Epub 2017 Oct 10. Ann Hematol. 2018. PMID: 28993857
Refractory diffuse large B-cell lymphoma after first-line immuno-CT: Treatment options and outcomes.
Filliatre-Clement L, Maucort-Boulch D, Bourbon E, Karlin L, Safar V, Bachy E, Sesques P, Ferrant E, Bouafia F, Lazareth A, Ghergus D, Coiffier B, Traverse Glehen A, Salles G, Ghesquieres H, Sarkozy C. Filliatre-Clement L, et al. Among authors: safar v. Hematol Oncol. 2018 May 2. doi: 10.1002/hon.2512. Online ahead of print. Hematol Oncol. 2018. PMID: 29722049
Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B-cell lymphoma, a clinico-pathological series of 25 cases.
Aussedat G, Traverse-Glehen A, Stamatoullas A, Molina T, Safar V, Laurent C, Michot JM, Hirsch P, Nicolas-Virelizier E, Lamure S, Regny C, Picquenot JM, Ledoux-Pilon A, Tas P, Chassagne-Clément C, Manson G, Lemal R, Fontaine J, Le Cann M, Salles G, Ghesquières H, Copie-Bergman C, Sarkozy C. Aussedat G, et al. Among authors: safar v. Br J Haematol. 2020 Apr;189(2):244-256. doi: 10.1111/bjh.16331. Epub 2020 Feb 6. Br J Haematol. 2020. PMID: 32030731 Free article.
Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group.
Le Gouill S, Beldi-Ferchiou A, Alcantara M, Cacheux V, Safar V, Burroni B, Guidez S, Gastinne T, Canioni D, Thieblemont C, Maisonneuve H, Bodet-Milin C, Houot R, Oberic L, Bouabdallah K, Bescond C, Damaj G, Jaccard A, Daguindau N, Moreau A, Tilly H, Ribrag V, Delfau-Larue MH, Hermine O, Macintyre E. Le Gouill S, et al. Among authors: safar v. Lancet Haematol. 2020 Nov;7(11):e798-e807. doi: 10.1016/S2352-3026(20)30291-X. Epub 2020 Sep 21. Lancet Haematol. 2020. PMID: 32971036 Clinical Trial.
Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma.
Lemonnier F, Safar V, Beldi-Ferchiou A, Cottereau AS, Bachy E, Cartron G, Fataccioli V, Pelletier L, Robe C, Letourneau A, Missiaglia E, Fourati S, Moles-Moreau MP, Delmer A, Bouabdallah R, Voillat L, Becker S, Bossard C, Parrens M, Casasnovas O, Cacheux V, Régny C, Camus V, Delfau-Larue MH, Meignan M, de Leval L, Gaulard P, Haioun C. Lemonnier F, et al. Among authors: safar v. Blood Adv. 2021 Jan 26;5(2):539-548. doi: 10.1182/bloodadvances.2020003081. Blood Adv. 2021. PMID: 33496747 Free PMC article. Clinical Trial.
Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified.
Bourbon E, Maucort-Boulch D, Fontaine J, Mauduit C, Sesques P, Safar V, Ferrant E, Golfier C, Ghergus D, Karlin L, Lazareth A, Bouafia F, Pica GM, Orsini-Piocelle F, Rocher C, Gros FX, Parrens M, Dony A, Rossi C, Ghesquières H, Bachy E, Traverse-Glehen A, Sarkozy C. Bourbon E, et al. Among authors: safar v. Blood Adv. 2021 Aug 24;5(16):3227-3239. doi: 10.1182/bloodadvances.2021004515. Blood Adv. 2021. PMID: 34427583 Free PMC article.
Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study.
Sarkozy C, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Damaj G, Gastinne T, Tessoulin B, Ribrag V, Casasnovas O, Haioun C, Houot R, Jardin F, Van Den Neste E, Cheminant M, Morschhauser F, Callanan M, Safar V, Gressin R, Hermine O, Le Gouill S. Sarkozy C, et al. Among authors: safar v. J Clin Oncol. 2024 Mar 1;42(7):769-773. doi: 10.1200/JCO.23.01586. Epub 2023 Dec 18. J Clin Oncol. 2024. PMID: 38109684
33 results